The following is a copy of a press release issued by Primo Biotechnology on October 14, 2026
WEST VALLEY CITY, Utah and TAIPEI CITY, Taiwan – Oct. 14, 2026 – Nusano, a physics company transforming the production of radioisotopes, and Primo Biotechnology, a Taiwan-based radiopharmaceutical developer, today announced a multi-isotope supply agreement to support Primo’s radiotheranostic product pipeline and strengthen access to critical medical isotopes used in the development of targeted cancer therapies.
The agreement gives Primo access to Nusano-produced radioisotopes, including lutetium-177, actinium-225, indium-111, zirconium-89, and terbium-161.
“At Primo, we are working to advance innovative radiotheranostic medicines that can improve the lives of cancer patients,” said Dr. Ya-Yao Huang, Chairman and CEO of Primo Biotechnology. “That work depends on reliable access to critical medical isotopes, and this agreement with Nusano strengthens our ability to develop and deliver next-generation radiotherapeutics with greater confidence.”
Nusano’s radioisotope production platform combines established technologies from universities and world-class research centers with the company’s patented particle acceleration technology. The result is one of the first significant advancements in radioisotope production in decades: a smaller, more efficient platform capable of simultaneously manufacturing up to 12 different radioisotopes.
“Radiotherapeutic developers need dependable access to radioisotopes to move programs from discovery to clinical impact,” said Howard Lewin, Nusano co-founder and Chief Product Development Officer. “Nusano’s production platform is built to deliver that reliability, with the capacity and flexibility to grow and adapt with our customers’ needs. We are proud to establish a supplier relationship with Primo and look forward to supporting their pipeline of next-generation cancer therapies.”
# # #
About Primo
Primo Biotechnology is dedicated to driving the development of next-generation radiotheranostic drugs. Guided by its core philosophy, “Beginning with Precise Diagnosis, Ending with Precise Treatment,” the company has established the Primo-X Radiotheranostic Platform, which encompasses drug R&D, clinical translation, PIC/S GMP manufacturing, hospital integration, and international collaboration. Primo Biotechnology actively collaborates with domestic and global partners to accelerate the development of precision oncology, support the upgrading of Taiwan’s radiopharmaceutical industry, and bring the benefits of innovative nuclear medicine theranostics to more patients. For more information, please follow Primo Biotech on Facebook and LinkedIn.
About Nusano
Headquartered in West Valley City, Utah, Nusano is a privately held physics company working to stabilize supply chains, advance American national security by reducing dependency on foreign supply, and enable once-in-a-generation innovations in fields ranging from healthcare to nuclear energy. The company is commercializing platform technologies for radioisotope production, stable isotope enrichment, and advanced separation techniques. Together, these proprietary systems and methods are poised to supply the fight against cancer, fuel the nuclear renaissance, and deliver critical minerals for the modern world. For more, visit nusano.com.
Contacts:
- Scott Larrivee, Nusano, scott.larrivee@nusano.com, (608) 345-6629
- Sunny Chen, Primo, sunny.chen@primobt.com, (+886) 2-2537-1160
